Hearing Aid: Decibel Therapeutics CEO Laurence Reid Talks to Close to the Edge

Taking a gene therapy approach, Decibel targets various forms of hereditary deafness (single-gene disorders) as well as other auditory and balance disorders.

By Kevin Davies, PhD
-
0

In Close to the Edge, Episode 6, Decibel Therapeutics CEO Laurence Reid, PhD, talks about his career highlights and turning points leading up to his role at Decibel; the company’s strategy and prospects; its business partnerships including a manufacturing deal with Catalent; the future of genetic therapies; and the pain of England’s defeat in the final of EURO 2020 . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge

Previous articleSelf-Injecting Pill Could Allow Oral Delivery of Monoclonal Antibody and Other Protein Drugs
Next articleConnecting the Elements of Bioprocessing Operations

RELATED CONTENTMORE FROM AUTHOR